Robert Malone, who believes the U.S. government has “reality-bending information-control capabilities,” will guide the future ...

Recent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...

The rewriting of government recommendations will make the effort to get vaccine doses into arms exponentially more difficult, ...

BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.

President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...

Researchers identify SARS-CoV-2`s protective mechanism, offering potential targets for new Covid therapies and vaccine ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...